[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs : Highlights des ASCO-Meetings 2019.
Adverse effects
Head and neck neoplasms
Neoplasm metastatis
Neoplasm recurrence, local
R/M-HNSCC
Journal
HNO
ISSN: 1433-0458
Titre abrégé: HNO
Pays: Germany
ID NLM: 2985099R
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
9
11
2019
medline:
18
12
2019
entrez:
9
11
2019
Statut:
ppublish
Résumé
The contributions presented at this year's ASCO conference on treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) focused on systemic therapies, as in recent years. Two phase III studies-TPExtreme and Keynote-048-are expected to change clinical practice in first-line treatment of R/M-HNSCC. Abstracts and presentations from this year's ASCO Annual Meeting on R/M-HNSCC were screened and checked for clinical relevance. TPExtreme, a randomized phase III trial, could show less toxicity and similar overall survival in patients treated with docetaxel, cisplatin, and cetuximab (TPEx regimen) compared to standard first-line therapy with the Extreme regimen (cisplatin, 5‑fluorouracil [5-FU], cetuximab), albeit failing its endpoint of significantly improved survival. The randomized phase III Keynote-048 study could show a significant survival benefit in all patients treated with pembrolizumab, 5‑FU, and cis-/carboplatin compared to Extreme. When selected patients (PD-L1 CPS ≥1 and ≥20) were treated with pembrolizumab monotherapy, they showed increased overall response rates in contrast to patients treated with Extreme. Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine.
Sections du résumé
BACKGROUND
BACKGROUND
The contributions presented at this year's ASCO conference on treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) focused on systemic therapies, as in recent years. Two phase III studies-TPExtreme and Keynote-048-are expected to change clinical practice in first-line treatment of R/M-HNSCC.
MATERIALS AND METHODS
METHODS
Abstracts and presentations from this year's ASCO Annual Meeting on R/M-HNSCC were screened and checked for clinical relevance.
RESULTS
RESULTS
TPExtreme, a randomized phase III trial, could show less toxicity and similar overall survival in patients treated with docetaxel, cisplatin, and cetuximab (TPEx regimen) compared to standard first-line therapy with the Extreme regimen (cisplatin, 5‑fluorouracil [5-FU], cetuximab), albeit failing its endpoint of significantly improved survival. The randomized phase III Keynote-048 study could show a significant survival benefit in all patients treated with pembrolizumab, 5‑FU, and cis-/carboplatin compared to Extreme. When selected patients (PD-L1 CPS ≥1 and ≥20) were treated with pembrolizumab monotherapy, they showed increased overall response rates in contrast to patients treated with Extreme.
CONCLUSION
CONCLUSIONS
Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine.
Identifiants
pubmed: 31701170
doi: 10.1007/s00106-019-00773-4
pii: 10.1007/s00106-019-00773-4
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
898-904Références
Lancet Oncol. 2013 Jul;14(8):697-710
pubmed: 23746666
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Ann Oncol. 2014 Mar;25(3):682-8
pubmed: 24567516
Ann Oncol. 2015 Sep;26(9):1941-7
pubmed: 26109631
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Immunotherapy. 2018 Mar;10(3):163-165
pubmed: 29370724
Oral Oncol. 2017 May;68:103-113
pubmed: 28325631
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Oncotarget. 2019 Jun 11;10(39):3833-3834
pubmed: 31231462